AP NEWS

INVESTOR ALERT: Investigation of Trevena Announced by Holzer & Holzer, LLC

October 11, 2018

ATLANTA--(BUSINESS WIRE)--Oct 11, 2018--Holzer & Holzer, LLC is investigating whether certain statements issued by Trevena, Inc. (“Trevena” or the “Company”) (NASDAQ: TRVN) complied with federal securities laws. On October 9, 2018, the minutes from Trevena’s April 28, 2016 meeting with the Food and Drug Administration (“FDA”) were released, which disclosed that the FDA “did not agree” with several aspects of Trevena’s Phase 3 study for Oliceridine. The price of Trevena’s stock declined following the report.

If you purchased Trevena common stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Marshall P. Dees, Esq. at mdees@holzerlaw.com, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181011005723/en/

CONTACT: Holzer & Holzer, LLC

Corey D. Holzer, Esq., 888-508-6832 (toll-free)

cholzer@holzerlaw.com

KEYWORD: UNITED STATES NORTH AMERICA GEORGIA

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL PROFESSIONAL SERVICES LEGAL FDA

SOURCE: Holzer & Holzer, LLC

Copyright Business Wire 2018.

PUB: 10/11/2018 12:16 PM/DISC: 10/11/2018 12:16 PM

http://www.businesswire.com/news/home/20181011005723/en

AP RADIO
Update hourly